Protocol Ledger

NCT04512001 · Phase III · COMPLETED

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

Interventional Phase III clinical trial protocol NCT04512001 sponsored by Fresenius Kabi SwissBioSim in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-03 Enrollment: 604 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04512001
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)604 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04512001
Protocol FieldVerified Registry Value
NCT IdentifierNCT04512001
Consolidated Lead SponsorFresenius Kabi SwissBioSim
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment604 participants (ACTUAL)
Registered Start Date2020-08-03
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI